Toripalimab and capecitabine after chemoradiotherapy for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the immunotherapy drug toripalimab and the chemotherapy pill capecitabine after standard chemoradiotherapy can help prevent esophageal cancer from coming back. It's for people with squamous cell esophageal cancer that hasn't spread far and who have just finished chemoradiotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell carcinoma of the esophagus (a type of esophageal cancer).
- Your cancer is locally advanced (stage I to IVA, or stage IVB with spread only to lymph nodes above the collarbone).
- You have completed a course of chemoradiotherapy (chemo and radiation) without your cancer getting worse.
- You have not had any other cancer treatment (like surgery or more drugs) after finishing chemoradiotherapy.
- You are between 18 and 75 years old, in generally good health (able to care for yourself), and have adequate organ function.
- You do not have serious conditions like an esophageal fistula, bleeding, active infections, or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of treatments for people with advanced esophageal cancer that can't be removed by surgery. It uses a targeted therapy called surufatinib along with chemo-immunotherapy and radiation to see if it can shrink the tumor before further treatment.
This trial tests whether continuing immunotherapy (toripalimab) after surgery helps prevent esophageal cancer from coming back. It is for people who already had surgery for squamous cell esophageal cancer after receiving immunotherapy plus chemotherapy before surgery.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemoradiation before surgery helps people with a type of esophageal cancer. It is for patients whose cancer has not spread to other organs and who have not had treatment before.
This study tests whether adding a drug called toripalimab after standard chemoradiation can help older adults with esophageal cancer. The goal is to see if this treatment can keep the cancer from coming back after initial therapy.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a new immunotherapy drug called toripalimab, given before, during, and after standard radiation and chemotherapy for esophageal cancer that hasn't spread. The goal is to see if adding this drug can improve outcomes for patients.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.